Leman Yel | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Leman Yel is active.

Explore More

Publication

Featured researches published by Leman Yel.

Journal of Clinical Immunology | 2017

Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”

Daniel Suez; Mark R. Stein; Sudhir Gupta; Iftikhar Hussain; Isaac Melamed; Kenneth Paris; Amy Liebl Darter; Christelle Bourgeois; Sandor Fritsch; Heinz Leibl; Barbara McCoy; David Gelmont; Leman Yel

Author(s): Suez, Daniel; Stein, Mark; Gupta, Sudhir; Hussain, Iftikhar; Melamed, Isaac; Paris, Kenneth; Darter, Amy; Bourgeois, Christelle; Fritsch, Sandor; Leibl, Heinz; McCoy, Barbara; Gelmont, David; Yel, Leman

Middleton's Allergy (Eighth Edition) | 2014

10 – Molecular Biology and Genetic Engineering

Sudhir Gupta; Leman Yel

The Journal of Allergy and Clinical Immunology | 2018

Onboarding Experience of Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin 10%

Sudhir Gupta; Iftikhar Hussain; Kenneth Paris; Mark R. Stein; Barbara McCoy; Ping Wang; Christopher J. Rabbat; Leman Yel

Revista Alergia México | 2018

Non-interventional post-marketing safety study on the long-term safety of HyQvia (global)

Lina Laguado; Katharina Fielhauer; Andras Nagy; Christopher J. Rabbat; Barbara McCoy; Heinz Leibl; Leman Yel

Revista Alergia México | 2018

Local adverse reaction rates decreased over time during treatment with recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin G (fSCIG) in patients with primary immunodeficiency diseases in the fSCIG phase 3 studies

Lina Laguado; Mark R. Stein; Richard L. Wasserman; Isaac Melamed; Sudhir Gupta; Lisa Kobrynski; Arye Rubinstein; Christopher J. Rabbat; Werner Engl; Barbara McCoy; Heinz Leibl; Leman Yel

Revista Alergia México | 2018

Long-term adverse events, efficacy, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin in patients aged < 18 years with primary immunodeficiency diseases

Lina Laguado; Richard L. Wasserman; Isaac Melamed; Lisa Kobrynski; Sudhir Gupta; Werner Engl; Heinz Leibl; Leman Yel

The Journal of Allergy and Clinical Immunology | 2017

Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive Studies

Richard L. Wasserman; Sudhir Gupta; Mark R. Stein; Isaac Melamed; Jennifer M. Puck; Werner Engl; Heinz Leibl; Christopher J. Rabbat; Leman Yel

The Journal of Allergy and Clinical Immunology | 2017

Analysis of Safety and Tolerability Data in Pediatric Patients with Primary Immunodeficiency Diseases from Two Phase 2/3 Studies of Human Immune Globulin Subcutaneous, 20%

Kenneth Paris; Elie Haddad; Iftikhar Hussain; Nicholas Brodszki; Amy Liebl Darter; Werner Engl; Barbara McCoy; Leman Yel

The Journal of Allergy and Clinical Immunology | 2017

Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs)

Sudhir Gupta; Mark R. Stein; Isaac Melamed; Iftikhar Hussain; Kenneth Paris; Werner Engl; Barbara McCoy; Christopher J. Rabbat; Leman Yel

The Journal of Allergy and Clinical Immunology | 2017

A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America

Daniel Suez; Gregely Krivan; Stephen Jolles; Iftikhar Hussain; Mark R. Stein; Sudhir Gupta; Kenneth Paris; Martin van Hagen; Nicholas Brodszki; Barbara McCoy; Leman Yel

Explore More